Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02579642

Organisation Name: University of Alberta

Overal Status: Completed

Start Date: October 2015

Last Update: April 28, 2021

Lead Sponsor: University of Alberta

Brief Summary: Ketamine has been used successfully as the sole medication for anesthesia in the setting of electroconvulsive therapy (ECT), and has more recently been studied as an adjunct agent in combination with propofol (the most commonly used anesthetic agent) to induce anesthesia for ECT. New literature postulates an anti-depressant effect of ketamine, which in ECT specifically may be helpful with regards to the overall goals of therapy (i.e. ECT indicated for severe or treatment-resistant depression).

Current research focusing on ketamine with respect to its anti-depressant effect suggests it may even represent an alternative to ECT. This study will seek to determine whether ketamine when used in low-doses as an adjunct to propofol-based anesthesia for ECT has anti-depressant effects and whether it influences the characteristics of recovery from anesthesia in the ECT setting (i.e. vital sign parameters such as blood pressure and heart rate, quality of recovery, etc.).

Conditions:
  • Depressive Disorder


Total execution time in seconds: 0.2465648651123